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ABSTRACT
The HRAS promoter contains immediately upstream
of the transcription start site two neighboring
G-elements, each capable of folding into a G-
quadruplex structure. We have previously found that
these G-quadruplexes bind to the zinc-finger tran-
scription factors MAZ and Sp1. In the present study
we have examined the interaction between the HRAS
promoter and MAZ, demonstrating for the first time
that the protein unfolds the G-quadruplex structures.
We also demonstrate that MAZ-GST, in the pres-
ence of the complementary strands, promotes a rapid
transformation of the two HRAS quadruplexes into
duplexes. By a mutational analysis of the HRAS G-
elements, we dissected the MAZ-binding sites from
the quadruplex-forming motifs, finding that the two
neighboring G-quadruplexes bring about a dramatic
repression of transcription, in a synergistic manner.
We also discovered that the two G-quadruplexes are
strong targets for small anticancer molecules. We
found that a cell-penetrating anthratiophenedione
(ATPD-1), which binds tightly to the G-quadruplexes
(T > 15◦C), promotes the total extinction of HRAS
transcription. In contrast, when one of the two G-
quadruplexes was abrogated by point mutations,
ATPD-1 repressed transcription by only 50%. Our
study provides relevant information for the rationale
design of targeted therapy drugs specific for the
HRAS oncogene.
INTRODUCTION
The ras genes encode for GTP-binding proteins of 21 kDa
(p21RAS) sharing a high degree of homology (1). Proteins
p21RAS regulate the response of the cell to a variety of extra-
cellular stimuli including mitogens and differentiation fac-
tors (2). The ras genes have similar primary structures: five
exons, the first of which is non-coding, conserved splicing
sites and introns of different length and sequence (1). In
many human tumors, the ras genes are transformed into
oncogenes by point mutations, frequently occurring in exon
1, at codon 12, 13 or 61 (3). Mutated p21RAS shows a de-
creased capacity to hydrolyze GTP to GDP, thus remain-
ing locked into the activated state that constitutively stimu-
lates cell proliferation (3). HRAS is frequently mutated in
urinary bladder tumors (4) and its degree of overexpres-
sion correlates with tumor invasiveness (5,6). Mutations
and overexpression contribute to the tumorigenesis of uri-
nary bladder cancer (7). So far, the therapeutic strategies
proposed to cure bladder cancer or to sensitize bladder can-
cer cells to conventional chemotherapy are based on the use
of farnesyltransferase inhibitors. These compounds are able
to block the binding of the ras protein to the cell mem-
brane or inhibit the downstream RAS/MEK/ERK path-
way, which stimulates cell growth in urinary cancer cells (8).
In the present work we have focused on the promoter of the
HRAS gene, in order to identify structure-function relation-
ships that could be useful for the rationale design of anti-
cancer drugs. We had previously found by chromatin im-
munoprecipitation that the transcription factors MAZ and
Sp1 localize within the HRAS promoter, at two neighbor-
ing G-rich sequences named by us hras-1 and hras-2. Each
sequence, being composed of runs of guanines (G-runs),
folds into a stable G-quadruplex structure in the presence
of potassium (9). Todd and Neidle (10) first discovered a
correlation between quadruplex-forming sequences in the
immediate upstream region of certain human genes and the
occurrence of zinc-finger binding motifs (Sp1). After them,
Kumar et al. (11) revealed that zinc-finger motifs (Sp1 and
MAZ) co-localize with the quadruplex-forming sequences
in human, chimpanzee, mouse and rat. In our laboratory
we have shown thatMAZ activates the expression ofHRAS
and KRAS in human and mouse (9,12). The function of
MAZ in gene promoters is rather complex, as it can both
activate (13,14) or inhibit (15–17) gene expression.
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In this study we have investigated how MAZ and the
HRAS quadruplexes influence transcription. We demon-
strate for the first time that MAZ, a transcription factor
that recognizes blocks of guanines, is able to unfold both
the parallel and antiparallel HRAS quadruplexes and to
promote their hybridization to the complementary C-rich
strands, thus bringing back the duplex conformation: a crit-
ical step for the assembly of the transcription machinery.
By a systematic mutational analysis of theHRAS promoter
G-elements, we dissected the MAZ-binding sites from the
quadruplex-forming motifs, finding that the two neighbor-
ing G-quadruplexes behave as a molecular on–off switch
with a strong impact on transcription repression. We also
report that the two quadruplex structures can function as
targets for therapeutic molecules designed to repress onco-
genic HRAS in bladder cancer cells. We have found that
the HRAS promoter is completely blocked when both G-
quadruplexes are targeted by an antrathiophenedione lig-
and (ATPD-1), whereas the promoter activity is reduced
by ∼50% when only one G-quadruplex is targeted. We
also provide a mechanistic insight on how ATPD-1 reduces
HRAS gene expression. In summary, in this study we shed
light on howHRAS transcription is regulated and how G4-
DNA specific binders repress oncogenic HRAS in urinary
bladder cancer cells.
MATERIALS AND METHODS
Oligonucleotides and fluorophore-labelled oligonucleotides
The following oligonucleotides, free and labeled at the 5′
and 3′ ends with FAM and TAMRA, have been purchased







T (F-hras2-T); where T = tetramethyl rhodamine; F =
6-carboxy-fluorescein. Oligonucleotide aliquots in milli-Q
water were kept at -80◦C.
Recombinant MAZ-GST and EMSA
Recombinant MAZ tagged to glutathione S-tranferase
(GST) was expressed in Escherichia coli BL21 DE3 plys
by using plasmid pGEX-hMAZ (9). The bacteria were
grown for 1–2 h at 37◦C to an A600 of 0.6–0.8 prior to
induction with isopropyl 1-thio--D-galactopyranoside (1
mM final concentration). Cells were allowed to grow with
4 M Zn(CH3COO)2 for 18 h before harvesting. The
cells were centrifuged at 6240 × g, 4◦C, the supernatant
was removed and the pellet was resuspended in phosphate
buffered saline (PBS) containing 1 mM phenylmethylsul-
fonyl fluoride. The bacteria were lysed by sonication and
centrifuged for 30′, 4◦C, 34540 × g. Glutathione Sepharose
4B resin (GE Healthcare) (50% slurry in PBS) was added
to the supernatant obtained in the previous step and incu-
bated for 1 h, 4◦C, on a shaker. The mix was centrifuged for
5 min at 500 × g and the pellet was washed 3× with PBS.
MAZ-GST was eluted from the resin with a buffer com-
posed by 50 mM Tris-HCl, pH 8 and 10 mM reduced glu-
tathione. The purity and homogeneity were confirmed by
sodium dodecyl sulphate-polyacrylamide gel electrophore-
sis (not shown). Protein concentration determined by Brad-
ford method. The interaction between MAZ-GST and the
HRAS duplexes in binding buffer (20 mM Tris-HCl pH
8, 8% glycerol, 100 M MgCl2, 50 M Zn-acetate, 1 mM
DTT, 2.5 ng/l polydIdC, 1 mMNa3VO4, 5 mMNaF; 1%
phosphatase inhibitor cocktail, Sigma) added with KCl as
specified in figure captions, was analyzed by electrophoretic
mobility shift assays (EMSA), 5% polyacrylamide gel in
Tris-borate (TB 1×) at 20◦C, as previously described (12).
DMS footprinting and circular dichroism
DMS footprinting of hras-1 and hras-2 in 100mMCsCl and
140 mM KCl was performed as previously described (9).
TheCD spectra have been recorded on a JASCO J-600 spec-
tropolarimeter equipped with a thermostatted cell holder, 3
M oligonucleotide in 50 mM Tris-HCl, pH 7.4, 100 mM
KCl.
FRET experiments
FRET experiments with oligonucleotides F-hras1-T and
F-hras2-T, tagged at the 5′ and 3′ ends with FAM and
TAMRA, were carried out on a Microplate Spectrofluo-
rometer System (Perkin Elmer 2300 Enspire, USA). Each
sample contained 50 l of 200 nM dual-labeled oligonu-
cleotide in 50 mM Tris-HCl buffer, pH 7.4, 50 M Zn ac-
etate, KCl and MAZ-GST, as specified in the figure cap-
tions. The samples were incubated at 37◦Cas specified in the
text. Emission spectra were obtained setting the excitation
wavelength at 480 nm and recording the emission from 500
to 650 nm. FRET-melting experiments were performed on
a real-time polymerase chain reaction apparatus (CFX96,
BioRad, Hercules, CA). FRET-melting experiments were
obtained as follows: 5 min equilibration at 20◦C, 5 min;
stepwise increase of temperature up to 95◦C (1◦C/min);
number of cycles, 76.
FRET efficiency (E) was calculated from the fluorescence
intensity of the donor D in the presence (IDA) and absence
(ID) of the acceptor as:
E = 1 − IDA
ID
I DA and ID were measured in same buffer under iden-
tical concentrations (ID was obtained by transforming the
dual-labeled oligonucleotide into the corresponding duplex
in which the fluorophores are at a distance for which FRET
= 0). FRET efficiency values were converted to distances






where R is the distance (A˚) and R0 is the Fo¨ster distance
(defined as the distance at which energy transfer is 50%
of the maximum value). The Fo¨ster distance (R0) between
FAM and TAMRA is 50 A˚ (18–20).
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Filter binding assay
We performed a double-filter method as previously de-
scribed (21). A nitrocellulose membrane was incubated for
10 min in 0.4 M KOH at 4◦C, washed with water and equi-
librated in 20 mM Tris HCl pH 8, 8% glycerol; Immobilon-
NY+ (Millipore) was equilibrated in the same buffer. Im-
mobilon membrane was placed below the nitrocellulose
membrane in a filter binding apparatus Minifold I (What-
man) where the upper membrane captures MAZ-GST with
or without bound DNA and the lower membrane traps
free DNA. Samples containing DNA and MAZ-GST, in-
cubated at 4 ◦C for 30 min in binding buffer (see EMSA)
added with KCl as specified in figure captions, were applied
to filters under vacuumandwashedwith binding buffer. Fil-
ters were dried, exposed for autoradiography and quanti-
fied using an Image Scanner controlled by ImageQuant TL
V2003.03 software (GE Healthcare).
Dual luciferase assays
Transfection was performed by mixing vector (250 ng/well)
pHRAS-luc ormutant vectorsMut-1,Mut-2,Mut-A,Mut-
B, Mut-C and Mut-D with 10 ng of control plasmid pRL-
CMV where Renilla luciferase was driven by the CMV pro-
moter (10 ng/well) using jet-PEI (Polyplus) as a transfecting
reagent. Vectors pHRAS-luc and mutant vectors expressed
firefly luciferase under the control of wild-type or mutant
HRAS promoters (Figure 5 shows the mutations) . Fire-
fly luciferase in cell lysates was measured and normalized
for Renilla luciferase. Luciferase assays were performed 48
and 72 h after transfection with Dual-Glo Luciferase Assay
System (Promega) following the supplier instructions. Sam-
ples were read on a Turner Luminometer and the relative
luminescence expressed as (T/C × 100) where T = firefly
luciferase/renilla luciferase in treated cells and C = firefly
luciferase/renilla luciferase in untreated cells.
Co-transfection experiments in T24 cells were carried out
by using mixtures containing 100 ng of pHRAS-luc or mu-
tant vector, 10 ng of pRL-CMV and 100 ng of pCMV-
MAZ or pcDNA3 plasmid (empty vector) as mass for con-
trol transfections. Each transfection was performed in trip-
licate. Plasmid pHRAS-luc, Mut-1 and Mut-2 were previ-
ously constructed in our laboratory (9). Instead, Mut-A,
Mut-B, Mut-C and Mut-D, obtained from pHRAS-luc by
site-directed mutagenesis, have been constructed by Gen-
Script, Piscataway, NJ.
RESULTS AND DISCUSSION
The HRAS promoter, upstream of the transcription start
site (TSS), contains several copies of the G-box 5′-
GGGCGGG, which is recognized by the transcription
factors MAZ and Sp1 [the consensus for MAZ is 5′-
(G/C)GG(C/A)GGG, while the consensus for Sp1 is 5′-
GGGCGGG (22–24)]. Upstream of the transcription start
sites there are two G-elements, hras-1 and hras-2, the first
of which contains one mismatched G-box, 5′-GGGCGGC,
and the second two perfect G-boxes, 5′-GGGCGG (Fig-
ure 1A). We have previously demonstrated by chromatin
immunoprecipitation that under in vivo conditions MAZ
is associated with both hras-1 and hras-2 sequences but
Figure 1. (A) Structure of the HRAS promoter upstream of TSS. The se-
quences of hras-1 (432–462, J00277) and hras-2 are shown. The binding
sites of MAZ and Sp1 are evidenced; (B) EMSA showing the binding of
MAZ-GST to hras-1 duplex, hras-2 duplex and hras-2 mutant duplex (see
sequences in panel A) in binding buffer (‘Materials andMethods’ section).
Left and middle gels were loaded as follows: 0, 0.5, 1, 1.5, 2, 2.5 and 3 g
MAZ-GST and duplex in lanes 1 to 7, respectively. Right gel was loaded
as follows: 3 gMAZ-GST and wild-type duplex (lane 1); 0.5, 1, 1.5, 2, 2.5
and 3 g MAZ-GST + mutant hras-2 duplex in lanes 2 to 7, respectively.
Sp1 only to hras-2 (9). This was also confirmed by biotin-
streptavidin pull-down and western blot assays: compared
to the amount of proteins in the nuclear extract, duplex
hras-2 enriched the eluted fractions of both MAZ and Sp1,
whereas duplex hras-1 only enriched MAZ (Supporting In-
formation S1). Together, these experiments identified MAZ
as a specific interactor of both hras-1 and hras-2 sequences.
As MAZ recognizes both HRAS G-elements, in the
present study we focus mainly on this zinc-finger transcrip-
tion factor. The binding of MAZ to duplexes hras-1 and
hras-2 was examined by EMSA, using recombinant MAZ-
GST (Figure 1B). It can be seen that 0.5 g of MAZ-GST
is sufficient to detect its binding to duplex hras-2, while the
binding to duplex hras-1 is observed at 2 g protein. This
suggests that MAZ-GST has more affinity for hras-2 than
for hras-1 (see also S1).Moreover, in agreement with the fact
that it harbors twoMAZ-binding sites, duplex hras-2 forms
two DNA–protein complexes, one with a 1:1 stoichiometry,
the other with a 1:2 stoichiometry. As we expected, when
one of the two MAZ-binding sites was abrogated by point
mutations, the 1:2 complex was not detected in the gel (Fig-
ure 1B).
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As sequences hras-1 and hras-2 are composed of runs of
guanines, they are inclined to fold into G-quadruplex struc-
tures (Figure 2A–D) (9). DMS-footprinting was used to de-
termine that these guanines are involved in the formation of
G-quadruplexes. All hras-1 guanines are reactive to DMS
in 100 mM CsCl, while in 140 mM KCl only G8 and G14
are reactive. This unambiguously shows that G3–G5, G10–
G12, G17–G19, G23–G25 are involved in the formation of
the G-tetrad core of the quadruplex. Hras-1 shows a CD
spectrum with positive and negative ellipticities at 295 and
256 nm, respectively, suggesting that the sequence folds into
an antiparallel quadruplex. CD and FRET experiments as
a function of temperature showed that hras-1 melts in a co-
operative manner with a biphasic profile in 100 mM KCl,
indicating that it folds into two quadruplexes with TM’s of
∼53 and ∼65◦C. Moreover, due to its moderate stability,
quadruplex hras-1 is unable to arrest Taq polymerase in
primer extension experiments, but it does so in the presence
of a G4 stabilizer (phthalocyanine) (S2,a).
Sequence hras-2, being composed of guanine blocks of
4 and 5 bases, can also fold into a G-quadruplex (Figure
2B,D). In CsCl all guanines react with DMS, but in 140
mM KCl the reactivity is only observed with G10, G12,
G13, G21 and G22. This indicates that G3–G5, G7–G9,
G14–G16 and G18–G20 should be engaged in the forma-
tion of the quadruplex. As the CD of hras-2 is dominated
by a strong positive ellipticity at 260 nm, we concluded that
it forms a parallel G-quadruplex. The TM of this structure
in 20 mM KCl is ∼77◦C, but in 100 mM KCl is >90◦C.
Primer extension experiment showed that quadruplex hras-
2 caused a strong stall of Taq polymerase, even in the ab-
sence of a G4 stabilizer, thanks to its high stability (S2,b).
Recent bio-informatic studies have shown that zinc-finger
transcription factors, such as MAZ and Sp1, co-localize
with quadruplex-forming motifs (11,25). In keeping with
this, we have previously found by EMSA that recombinant
MAZ-GST binds to both quadruplexes formed by hras-1
and hras-2 (9). Here, we examined the binding of MAZ-
GST to quadruplexes hras-1 and hras-2 also by a competi-
tion binding assay. Figure 3A shows that the DNA-protein
complexes between MAZ-GST and 32P-labeled hras-1 and
hras-2 duplexes are competed away by 10, 50, 100-fold ex-
cess of cold (hras-1 or hras-2) G-quadruplex. As duplex
hras-1 has only one MAZ-binding site, it forms with MAZ-
GST a 1:1 complex which is competed by a 10-fold ex-
cess of cold quadruplex hras-1. Duplex hras-2, having two
protein-binding sites, forms both 1:1 and 1:2 complexes
with MAZ-GST. The latter complex is competed by a 10-
fold excess cold quadruplex hras-2, suggesting that both
HRAS quadruplexes compete to a similar extent with their
duplex sequences. Instead, the 1:1 complex is competed by
a 100-fold excess G-quadruplex. This is in agreement with
the higher stability of the hras-2 duplex complex compared
to the hras-1 duplex complex.
To estimate the affinity of MAZ-GST for quadruplexes
hras-1 and hras-2, we have carried out a double-filter bind-
ing assay, as previously described (21). The G-quadruplexes
end-labeled with 32P andMAZ-GST have been incubated in
binding buffer containing 100 mMKCl (see ‘Materials and
Methods’ section). Free and MAZ-GST-bound quadru-
plexes were separated and immobilized on nylon and nitro-
cellulose, respectively. Typical dot blots are shown in Fig-
ure 3B. The fractions of bound quadruplexes were plotted
against MAZ-GST concentrations and the data best-fitted
to the Hill equation (Figure 3C). For quadruplex hras-1 we
obtained KD = 504 ± 84 nM, n = 1.6 ± 0.3, while for
quadruplex hras-2 we obtained KD = 207 ± 12 nM and
n = 1.4 ± 0.2, where n is the cooperative coefficient. As
n > 1, the binding between MAZ-GST and the quadru-
plexes is slightly cooperative. As a control, we incubated
the G-quadruplexes with bovine serum albumin (BSA) and
no binding was detected in the nitrocellulose membrane,
as expected. The KD values measured in this way presum-
ably underestimate the affinity of MAZ-GST for the two
G-quadruplexes as: (i) recombinant bacterially expressed
proteins do not carry the post-translational modifications
of the cellular analogues; (ii) upon binding to the protein,
the quadruplex is unfolded and assumes a conformation for
which the MAZ shows a lower affinity (see S3). The affin-
ity of MAZ-GST for the parallel hras-2 quadruplex is 2.4-
fold higher than for the antiparallel hras-1 quadruplex. The
KD’s between MAZ-GST and HRAS quadruplexes are not
so different from those reported for the binding of recom-
binant UP1, hRNP A1, nucleophosmin and nucleolin to
G4-DNA (26–28). Instead, the KD reported for the interac-
tion between cellular Sp1 and quadruplex cKIT is>10-fold
lower (29).
As MAZ binds to both quadruplex and duplex con-
formations of hras-1 and hras-2, we wanted to find out
for which one it shows more affinity. We found an an-
swer in the biotin-streptavidin pull-down/western blot as-
says which was done with biotin-labeled hras-1, hras-2 and
scrambled oligonucleotides as probes. Based on the ionic
strength of the NaCl solutions used for separating the pro-
tein from the DNA probes, we concluded that the affinity of
MAZdecreases as follows:HRAS duplex>HRAS quadru-
plex >> scrambled duplex or scrambled single strand (S3).
Next, we interrogated if recombinant MAZ-GST is
able to unfold the HRAS G-quadruplexes. The unfold-
ing process can be followed by fluorescence-resonance en-
ergy transfer (FRET), using hras-1 and hras-2 quadruplex-
forming sequences tagged at the 5′ and 3′ ends with FAM
(donor) and TAMRA (acceptor) [F-hras1-T, F-hras2-T]
(26,30,31). In Figure 4A we report the data obtained with
the antiparallel hras-1 quadruplex. In the presence of 50
mM KCl, by exciting the donor at 480 nm, both donor
(520 nm) and acceptor (575 nm) emit fluorescence, thanks
to the FRET effect (spectrum 1, quadruplex). The energy
transfer efficiency (E) of the folded state (0.79) was used
to measure the end-to-end distance in quadruplex hras-1,
∼40 A˚ [Figure 4B (i)]. This value is consistent with the
dimensions of the G-quadruplex [diameter ∼25 A˚, height
6.3 A˚ (32)], accounting for the presence at the quadruplex
ends of two extra nucleotides and the dye linkers. When the
G-quadruplex is hybridized to its complementary strand
(27Y), it loses its folded conformation and assumes a lin-
ear B-DNA duplex form. A short B-DNA duplex behaves
as rigid rod, its contour length can be calculated from the
distance between two base pairs of 3.4 A˚. In duplex hras-1
the donor and acceptor are separated by ∼87 A˚, a distance
at which FRET = 0 (spectrum 7, Figure 4A). To under-
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Figure 2. (A) Sequence of hras-1 and densitometric scans of DMS-footprintings in 100 mM CsCl and 140 mM KCl; (B) Sequence of hras-2 and densito-
metric scans of DMS-footprinting in 100 mM CsCl and 140 mMKCl; (C) CD spectra of hras-1 in 50 mM Tris-HCl pH 7.4, 100 mMKCl, T = 20, 30, 40,
50, 55, 60, 65, 70, 80 and 90◦C; (D) CD spectra of hras-2 in 50 mM Tris-HCl pH 7.5, 100 mM KCl, T = 20, 30, 40, 50, 55, 60, 65, 70, 80 and 90◦C.
stand if quadruplex F-hras1-T is unfolded by MAZ-GST,
we incubated for 2 h the quadruplex and protein at r =
1, 2 and 4 (r = [protein]/[quadruplex]) in 50 mM KCl and
measured the fluorescence between 500 and 650 nm (spec-
tra 4–6, Figure 4A). It can be seen that MAZ-GST brings
about a dramatic increase of the donor emission, resulting
from an increase of the reciprocal distance between donor
and acceptor: a structural change consistent with the dis-
ruption of the G-quadruplex. The end-to-end distance (R)
of quadruplex hras-1 increases with r from ∼40 up to ∼58
A˚ (inset). Comparing R obtained with hras-1 in the duplex
conformation (∼87 A˚) with R of hras-1 bound to MAZ-
GST (58 A˚, at r = 4), we may conclude that the quadru-
plex is open but not fully extended by the protein [Figure
4B (ii-iii)]. In other words, the G-quadruplex in the DNA–
protein complex should be unfolded but with the 5′ and 3′
ends within the Fo¨ster distance. That is why some emis-
sion at 575 nm is still present in the samples treated with
MAZ-GST. As a control, we heated MAZ-GST before be-
ing used and also replaced it with BSA (unspecific pro-
tein). In both cases no increase of donor fluorescence at
520 nm was observed (spectra 2 and 3). To further sup-
port our interpretation, we performed FRET-melting ex-
periments, reasoning that an unfolded quadruplex would
not give the typical quadruplex-to-single strand transition.
Figure 4C,D shows the melting curves (F versus T and –
dF/dT versus T) of quadruplex F-hras1-T in 50 mM KCl
before (curve 1) and after incubation for 2 h with MAZ-
GST at r = 1, 2 and 4 (curves 4–6), with heated MAZ-GST
(r = 4, curve 2) and with BSA (r = 4, curve 3). It can be
seen that neither heated MAZ-GST nor BSA change the
melting profile of the quadruplex. In contrast, MAZ-GST
promotes, in a dose-response manner, a complete extinction
of the quadruplex-to-single strand transition. This strongly
suggests that in the DNA–protein complex, the quadruplex
structure is disrupted byMAZ-GST.When the GSTmoiety
of the protein was incubated with the quadruplex, no effect
on melting was observed (not shown).
We have also examined the impact of MAZ-GST on the
parallel hras-2 quadruplex, at various KCl concentrations
(10, 25, 50, 75, 100 and 140 mM) (Figure 4E). In this KCl
concentration range, hras-2 is folded (spectra 1–6), and the
distance between the fluorophores is ∼44 A˚. The transfor-
mation of quadruplex hras-2 into a linear B-DNA confor-
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Figure 3. (A) EMSA competition assay. The DNA–protein complexes be-
tween radiolabeled duplex hras-1 and duplex hras-2 and MAZ-GST are
competed away by excess (10-, 50- and 100-fold) cold G-quadruplex; (B)
Typical dot-blot assay showing the binding of MAZ-GST to quadruplex
hras-1 and hras-2 in binding buffer added with 100 mM KCl. Free and
bound G-quadruplexes, immobilized in nylon and nitrocellulose respec-
tively, are shown at various MAZ-GST concentrations. As a control a dot
blot with BSA was performed. (C) The % of quadruplex bound to MAZ-
GST is plotted against the protein concentration. The experimental points
(average of two experiments, uncertainty ± 15%) have been best-fitted to
the Hill equation {f = [L]n/([L]n+ KD)} (Sigma Plot 11).
mation by its complementary strand (24Y) increases the flu-
orophore distance to ∼78 A˚. In the presence of MAZ-GST
(r = 4), the fluorescence of the donor increases (spectra 7–
12), as the protein unfolds the quadruplex. In 10 mM KCl,
the end-to-end distance jumps to∼61 A˚, which hints to a re-
markable opening of the quadruplex in comparisonwith the
distance between the two fluorophores in the corresponding
hras-2 duplex (∼78 A˚). At higher KCl concentrations the
quadruplex stability increases and the unfolding becomes
less efficient (the fluorophore distance decreases from 61 to
44 A˚, inset). Figure 4F reports the FRET-melting experi-
ments showing that quadruplex hras-2 has a TM of 76, 83
or >90◦C in 25, 50 and 100 mM KCl, respectively. When
the samples before melting were treated for 2 h with MAZ-
GST (r = 4), the melting curve at 25 mM KCl was totally
abrogated, but at 50 and 100 mM KCl it was partly abro-
gated, as the quadruplex TM is >80◦C. In 100 mM NaCl,
MAZ-GST unfolds quadruplex hras-2 more efficiently, as
it has a lower TM (60◦C) (S4) and probably also a different
topology.
As far as we know, our data demonstrate for the first
time that MAZ, a zinc finger transcription factor recogniz-
ing blocks of guanine, is able to unfold G4-DNA.We tested
the capacity of MAZ to unfold other well-known quadru-
plexes and found that the protein was quite active against
the human telomere but not against theCMYC quadruplex
(not shown).
Next we reasoned that the unfolding byMAZ-GST of the
HRASG-quadruplexes should facilitate their hybridization
to the complementary pyrimidine strands (24 and 27Y) to
yield the corresponding B-DNA duplexes. To explore if the
quadruplex to B-DNA transformation at hras-1 and hras-
2 is facilitated by MAZ-GST, we set up an electrophoretic
assay (Figure 5). The hybridization of quadruplexes hras-1
and hras-2, end labeled at the 5′ end with 32P, to their com-
Figure 4. (A) Fluorescence emission of 200 nM quadruplex hras-1 tagged
at the 5′ and 3′ ends with FAM and TAMRA in 50 mM Tris-HCl, pH 7.4,
50 mM KCl, Ex = 480 nm. Spectra: 1, F-hras1-T; 2, F-hras1-T + heated
MAZ-GST (1:4); 3, F-hras1-T + BSA (1:4); 4–6, F-hras1-T + MAZ-GST
at r = 1, 2 and 4, respectively; 7, F-hras1-T hybridized to complementary
27Y strand to give the duplex. Each quadruplex–protein mixture has been
incubated for 2 h before FRET analysis. The inset shows the end-to-end
distance (R, A˚) of quadruplex hras-1 treated for 2 h with MAZ-GST (r
= 0, 1, 2 and 4), with BSA (r = 4) and with denatured MAZ-GST (r =
4) (MAZ D); (B) cartoon showing the three forms of hras-1 and for each
the calculated end-to-end distance; (C) Normalized fluorescence versus T
curves of quadruplex hras-1 in 50 mMTris-HCl pH 7.4, 50 mMKCl: curve
1, quadruplex hras-1; curve 2, quadruplex hras-1 treated for 2 hwith heated
MAZ-GST (r = 4); curve 3, quadruplex hras-1 treated for 2 h with BSA (r
= 4); curves 4, 5 and 6, quadruplex hras-1 treated for 2 h with MAZ-GST
at r = 1, 2 and 4, respectively; (D) –dF/dT versus T curves as in C; (E)
FRET of hras-2 tagged with FAM and TAMRA (F-hras2-T) in 10, 25, 50,
75, 100, 140 mM KCl (curves 1–6) and after treatment with MAZ-GST (r
= 4) (curves 12 to 7). The inset shows the decrease of the end-to-end dis-
tance of quadruplex hras-2 treated with MAZ-GST (r = 4) at various KCl
concentrations; (F) Normalized fluorescence versus T curves of quadru-
plex hras-2 in 25, 50 and 100 mM KCl with and without treatment with
MAZ-GST (r = 4) for 2 h.
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Figure 5. (A, left) Annealing between radiolabeled quadruplex hras-1 and
complementary Y-strand in binding buffer (‘Materials and Methods’ sec-
tion) added with 100 mM KCl. The amount of MAZ-GST was 3 g; (A,
right) Annealing between radiolabeled quadruplex hras-2 and complemen-
tary Y-strand in binding buffer added with 30 mM KCl. The amount of
MAZ-GST was 3 g. EMSA has been carried out with 12% PAGE in TB
at 20◦C; (B) Plots showing the fraction of duplex formed in the presence
or absence of MAZ-GST, as a function of time.
plementary strands was followed in 100 and 30 mM KCl,
respectively, because of their different stability. The quadru-
plexes incubated with two equivalents of complementary
strand, are transformed into duplexes on a timescale of
hours, at room temperature. In keeping with their different
thermal stability, quadruplex hras-1 (TM ∼53/65◦C, in 100
mM KCl) hybridizes to complementary 27Y in about 2 h
(lane 4, left gel), while quadruplex hras-2 (TM ∼76◦C, in 30
mM KCl) hybridizes to 24Y in a much longer time: after
8 h of incubation 60% hras-2 is still in quadruplex (lane 6,
right gel). However, when the annealing reaction was car-
ried out in the presence of excess recombinant MAZ-GST
(r = 10), duplex formation was much faster. After an in-
cubation of 0.1 h, quadruplex hras-1 was completely trans-
formed into B-DNA (lane 8, left gel), while 23% of hras-2
was still in quadruplex (lane 8, right gel). The duplex formed
during the annealing of quadruplex hras-2 to 24Y, bound to
MAZ-GST, thanks to its high affinity for the protein, and
formed the expected 1:1 and 1:2 complexes. In contrast, un-
der the experimental conditions adopted, MAZ-GST did
not stably bind to duplex hras-1, as this target contains a
mismatched GGGCGGCMAZ-binding site of lower affin-
ity (the smeared bands suggest a duplex dissociation from
the protein). The percentage of formed hras-1 or hras-2 du-
plex (either free or bound to MAZ-GST) is reported as a
function of time in Figure 5B. The plots show that in the
presence of the complementary strands, an excess of MAZ-
Figure 6. (A) Point mutations inserted in hras-1 and/or hras-2 of the de-
signed mutant plasmids Mut-1, Mut-2, Mut-A, Mut-B, Mut-C and Mut-
D. The sites of MAZ in hras-1 and hras-2 are signed with rectangles; (B)
Scheme showing the presence of the quadruplex-formingmotif (top panel)
and MAZ-binding site (bottom panel) in the various plasmids. (C) % rel-
ative luciferase from wild-type and mutant plasmids.
GST (r = 10) rapidly transforms both hras-1 and hras-2
quadruplexes into the respective B-DNA duplexes.
To explore how the two neighboring G-quadruplexes, lo-
cated upstream of TSS, affectHRAS transcription, we pre-
pared a series of mutant plasmids, by introducing point
mutations in the hras-1 and/or hras-2 G-elements (Figure
6A). We first constructed a plasmid, pHRAS-luc, bearing
firefly luciferase driven by the human HRAS promoter (9).
From pHRAS-luc we obtained by site-directedmutagenesis
several mutant plasmids, where quadruplex formation was
abolished at hras-1 (Mut-1) or hras-2 (Mut-2, Mut C, Mut
D) or at both hras-1 and hras-2 (Mut-A andMut-B). As the
quadruplex-forming sequences overlap the MAZ-binding
sites, these were also modified by the point mutations. The
presence or absence in the constructed expression plasmids
of G4-DNA and/or MAZ-binding sites at hras-1 and hras-
2 is summarized in Figure 6B. Dual luciferase assays have
been carried out by transfecting T24 bladder cancer cells
with the constructed plasmids. The level of firefly luciferase
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expressed by the vectors was normalized to the level of Re-
nilla luciferase and the data obtained were referred to the
level of luciferase of wild type pHRAS-luc, which was set
to 100 (Figure 6C). Analyzing the data in terms of quadru-
plex formation at hras-1 and hras-2, we could conclude that
the two neighboring G-quadruplexes strongly lock the pro-
moter in an inactive state. Indeed, when quadruplex forma-
tion is abolished at hras-1 or hras-2, luciferase increases to
143 (Mut-1) or 492 (Mut-2). This means that the parallel G-
quadruplex structure at hras-2 is a stronger transcription re-
pressor than the antiparallel G-quadruplex at hras-1. As we
expected, there is a correlation between quadruplex stability
and repressor activity.However, when bothG-quadruplexes
are abrogated, luciferase increases up to 1225 (Mut-B), in-
dicating that the two G-quadruplexes extinct the promoter
activity in a synergistic manner. It is interesting to observe
that although Mut-A is not able to form either hras-1 or
hras-2 quadruplex, its luciferase level increases only up to
370. We wondered why Mut-A and Mut-B express differ-
ent levels of luciferase, though neither of them is capable to
form quadruplexes at hras-1 and hras-2. The answer can be
found in the scheme of Figure 6B, which shows the quadru-
plexes and MAZ-binding sites at hras-1 and hras-2, in the
various expression plasmids. The G-elements inMut-A and
Mut-B can only assume a duplex conformation, thanks to
the point mutations introduced (Figure 6A), but whileMut-
B has maintained the MAZ-binding sites at both hras-1
and hras-2, Mut-A has lost the MAZ-binding site at hras-1.
So, the data suggest that the simultaneous presence of the
MAZ-binding sites at hras-1 and hras-2 is essential for opti-
mal promoter activity and luciferase synthesis. When Mut-
2, Mut-C and Mut-D are compared with each other, a sim-
ilar conclusion can be drawn (Figure 6B). The three plas-
mids can only form quadruplex hras-1, but the two MAZ-
binding sites in Mut-2 drop to one in Mut-C and to zero in
Mut-D. The reduction of the number ofMAZ-binding sites
is accompanied by a luciferase decrease from 492 (Mut-2)
to 149 (Mut-C) and 93 (Mut-D). Again, these data demon-
strate that the activity of the HRAS promoter requires the
presence of MAZ at both hras-1 and hras-2.
We then asked how the wild-type and mutant HRAS
promoters responded to the overexpression of MAZ. The
wild type and mutant plasmids were co-transfected in T24
bladder cancer cells with pCMV-MAZ, a vector expressing
MAZ. The relative increase of luciferase caused by MAZ is
reported in Figure 7. It can be seen that wild-type pHRAS-
luc strongly responded to the overexpression ofMAZ, while
Mut-1 gave a weak response and the other mutant plasmids
practically did not respond. As stated above, in pHRAS-luc
and Mut-1, the HRAS promoter is locked into an inactive
state mainly by quadruplex hras-2, this structure being very
stable under physiological conditions (TM > 80◦C). In the
absence of any stimulus, the transcription rate of these vec-
tors is quite low (see Figure 6C). But when MAZ is over-
expressed, the protein promotes the transformation of the
hras-1 and hras-2 quadruplexes intoB-DNA.Consequently,
the transcription block is removed and luciferase produced
by pHRAS-luc increases 8-fold. Mut-1 responds to the
MAZoverexpression less efficiently than the wild-type plas-
mid because the mutations delete the MAZ-binding site at
hras-1 (optimal transcription requires both MAZ-binding
Figure 7. Dual luciferase assay in T24 cells transfected with wild-type
pHRAS-luc, Mut-1, Mut-2, Mut-A, Mut-B, Mut-C and Mut-D (HRAS
vector) or co-transfected with pCMV-MAZ (HRAS vector + pCMV-
MAZ). The % relative luciferase reported in ordinate is given by:
(LHV/LHV+M) x 100, where LHV is the luciferase expressed by the HRAS
vectors, LHV+M is the luciferase expressed by the HRAS and pCMV-MAZ
vectors.
sites at hras-1 and hras-2). By contrast, all the other mu-
tant vectors, which do not have the block due to quadruplex
hras-2 (see Figure 6B), are characterized by a high intrin-
sic transcription level. So, the overexpression of MAZ does
not further increase transcription. The data confirm that
HRAS transcription is strongly activated by MAZ, most
likely through the unfolding ofG4-DNA.We have also tried
to overexpress MAZ and Sp1 together, obtaining roughly
the same results as those observed with the overexpression
of only MAZ (not shown).
Given their critical role in transcription regulation, the
two neighboring G-quadruplexes can be targeted by small
ligands in order to downregulateHRAS: an oncogene play-
ing a key role in the pathogenesis of urinary bladder cancer
(5,6,33,34). These molecules should bind preferentially G4-
DNA instead of B-DNA, and consequently repress tran-
scription by increasing the stability of the G-quadruplexes.
This should inhibit the unfolding of the quadruplex by
MAZ and arrests cell growth. To support these hypothe-
ses, we used an antrathiophenedione (ATPD-1), which was
recently found to strongly bind to hras-1 (KD of 0.34 ±
0.07, TM of 12 and 22◦C, in 100 mM KCl) and hras-2
(KD of 0.27 ± 0.02, TM of 19◦C, in 10 mM KCl) quadru-
plexes (35). We first treated T24 cancer cells with ATPD-1
for 24 h, then with the expression vectors for further 48 h.
At the end of the incubation a dual luciferase assay was car-
ried out. The relative firefly luciferase values obtained with
wild-type and mutant plasmids, in absence and presence
of 2.5 and 5 M ATPD-1, are reported in the histogram
of Figure 8A. It shows that ATPD-1 completely represses,
in a dose-response manner, luciferase of wild-type plasmid
pHRAS-luc, bearing bothHRAS quadruplex-forming mo-
tifs. In contrast, the ligand reduced by ∼50% the luciferase
expressed by mutants Mut-1 and Mut-2, which bear only
one quadruplex-forming motif. This suggests that only one
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Figure 8. (A) Structure of ATPD-1 and scheme of the transfection exper-
iment. T24 cells were treated with ATPD-1 for 24 h, then transfected with
luciferase vector. Right panel shows the dual luciferase assay in T24 cells
treated with increasing amounts of ATPD-1 (2.5 and 5 M) and trans-
fected with wild-type pHRAS-luc or mutant Mut-1, Mut-2, Mut-A, Mut-
B, Mut-C and Mut-D; (B) EMSA showing the binding of MAZ-GST (2
g) to 20 nM quadruplex hras-1 in binding buffer containing increasing
amounts of ATPD-1 (r= 0, 1, 2, 4, 6 and 8); (C) FRET-melting of 200 nM
hras-1 after overnight incubation in 50mMKCl andATPD-1 at r= 0, 1, 2,
4, 6, 8; (D) FRET-melting curves of hras-1 (200 nM) treated with ATPD-1
(r = 0, 1, 2, 4, 6, 8) and MAZ-GST (400 nM); (E) as in D, but with 800
nM MAZ-GST. The curves in (B), (D) and (E) have been normalized to
the fluorescence at 80◦C (or 85◦C).
G-quadruplex is unable to block transcription completely.
As we expected, Mut-A and Mut-B being unable to form
any G-quadruplex, do not respond to ATPD-1. Instead
Mut-C and Mut-D respond to the ligand, as they have one
quadruplex-forming motif (hras-1).
ATPD-1 can repress transcription either by competing
with the binding of MAZ to the quadruplex structures
or, alternatively, by enhancing the stability of the HRAS
quadruplexes and thus making MAZ unable to unfold
them. The first hypothesis was tested by an electrophoretic
mobility shift assay. Figure 8B shows that quadruplex hras-
1 andMAZ-GST form two complexes with 1:1 and 1:2 sto-
ichiometries. The formation of these complexes is not in-
hibited by ATPD-1 at r = 0, 1, 2, 4, 6 and 8 (r = [ATPD-
1]/[hras-1]). This suggests that the ligand does not compete
with MAZ-GST for binding to the quadruplexes. A sim-
ilar result was obtained with quadruplex hras-2 (S5). We
therefore focused on the second hypothesis and tested if
MAZ-GST is able to unfold the HRAS G-quadruplexes in
the presence of ATPD-1. Figure 8C shows that an excess
of ATPD-1 over the hras-1 quadruplex (up to 8-fold), in-
creases the quadruplex TM from∼51/65 to 70◦C, in 50 mM
KCl. When the G-quadruplex was treated with either 2 or
4 equivalents of MAZ-GST in the presence of increasing
amounts of ATPD-1 (r = 0, 1, 2, 4, 6 and 8), it was com-
pletely disrupted at r= 1, 2 and 4, and partially disrupted at
r = 6. In contrast, when ATPD-1 was used at r = 8, MAZ-
GST was unable to unfold the G-quadruplex (Figure 8D,
E). This experiment provides a mechanistic insight into the
capacity of ATPD-1 to lower HRAS expression and arrest
cell growth in bladder cancer (35).
Our findings suggest that the two G-elements controlling
the expression of HRAS may serve as effective targets for
antigene G-quadruplex ligands.
CONCLUSION
In this study we have reported a systematic mutational anal-
ysis of theHRAS promoter at hras-1 and hras-2, by dissect-
ing the quadruplex-forming motifs from the MAZ-binding
sites. The results allow us to conclude that two neighbor-
ing G-quadruplexes upstream of TSS repress transcription
in a coordinated and efficient way. For the first time we
demonstrate by FRET experiments that recombinantMAZ
unfolds the HRAS G-quadruplexes. Thanks to this ability,
MAZ facilitates the hybridization of the G-quadruplexes
to the complementary strand, in order to reconstitute the
B-DNA duplex. Our data suggest that MAZ, a zinc-finger
transcription factor that recognizes runs of guanines, has
two functions in theHRAS promoter: remove the transcrip-
tion blockade caused by the neighboring G-quadruplexes
at hras-1 and hras-2, and activate transcription. In agree-
ment with the model proposed for CMYC (36), the duplex-
to-quadruplex transformation is likely to behave as an on–
off switch that controls transcription. This switch is an at-
tractive target for small therapeutic molecules. We have in-
deed observed a dramatic arrest of HRAS transcription
when we used a cell-penetrating anthrathiophenedione G4-
DNA ligand (ATPD-1) which tightly binds to the HRAS-
quadruplexes. The two neighboring G-quadruplexes that
control transcription promise to be attractive targets for an-
ticancer drugs specific for oncogenicHRAS: the key genetic
lesion leading to urinary bladder cancer in human.
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